The need to accelerate access to new drugs for multidrug-resistant tuberculosis;Accélérer l’accès à de nouveaux médicaments pour le traitement de la tuberculose multirésistante: Une nécessité qui s’impose;La necesidad de acelerar el acceso a nuevos fármacos para la tuberculosis multirresistente

Bulletin of the World Health Organization

Volumn 93, Issue 7, 2015, Pages 491-497

  Cox, Helen S ^a   Furin, Jennifer J ^b   Mitnick, Carole D ^c   Daniels, Colleen ^d   Cox, Vivian ^e   Goemaere, Eric ^e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c PARTNERS IN HEALTH   (United States)

^d Treatment Action Group   (United States)

^e MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; DELAMANID; LINEZOLID; MOXIFLOXACIN; NITROIMIDAZOLE; PRETOMANID; PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

DISEASE TREATMENT; DRUG; HEALTH POLICY; HEALTH RISK; MORTALITY RISK; TUBERCULOSIS;

ARTICLE; DISEASE TRANSMISSION; DRUG SENSITIVITY; DRUG TOLERABILITY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCALE UP; SYSTEM ANALYSIS; WORLD HEALTH ORGANIZATION; CLINICAL TRIAL (TOPIC); DRUG ADMINISTRATION; DRUG APPROVAL; HEALTH CARE DELIVERY; ORGANIZATION AND MANAGEMENT; POLICY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; POLICY; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 84936064942     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.14.138925     Document Type: Article

References (46)

1. Global tuberculosis report 2014. Geneva: World Health Organization; 2014.
2. Zhao Y, Xu S, Wang L, Chin D P, Wang S, Jiang G, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012 Jun 7;366(23):2161–70. http://dx.doi.org/10.1056/NEJMoa1108789
3. Dooley KE, Nuermberger EL, Diacon AH. Pipeline of drugs for related diseases: tuberculosis. Curr Opin HIV AIDS. 2013 Nov;8(6):579–85. http://dx.doi.org/10.1097/COH.0000000000000009
4. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia R F, Mahanyele R, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012 Jun;56(6):3271–6. http://dx.doi.org/10.1128/AAC.06126-11
5. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013 Jun;41(6):1393–400. http://dx.doi.org/10.1183/09031936.00125812
6. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2012 Apr;16(4):447–54. http://dx.doi.org/10.5588/ijtld.11.0451
7. Lessem E, Cox H, Daniels C, Furin J, McKenna L, Mitnick CD, et al. Access to new medications for the treatment of drug-resistant tuberculosis: Patient, provider and community perspectives. Int J Infect Dis. 2015 Mar;32:56–60. http://dx.doi.org/10.1016/j.ijid.2014.12.012
8. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE. 2009;4(9):e6914. http://dx.doi.org/10.1371/journal.pone.0006914
9. Toczek A, Cox H, du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013 Mar;17(3):299–307. http://dx.doi.org/10.5588/ijtld.12.0537
10. Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disord. 2007;7(1):5. http://dx.doi.org/10.1186/1472-6815-7-5
11. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva: World Health Organization; 2011.
12. Safety and efficacy trial of delamanid for 6 months in patients with multidrug resistant tuberculosis [Internet]. Bethesda: National Institutes of Health; 2015. Available from: https://clinicaltrials.gov/ct2/show/NCT01424670 [cited 2015 Apr 13].
13. NDA 204384. Accelerated approval. Silver Spring: Food and Drug Administration; 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/204384Orig1s000ltr.pdf [cited 2015 Apr 13].
14. Nunn AJ, Rusen ID, Van Deun A, Torrea G, Phillips P P, Chiang CY, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials. 2014;15:353.
15. Brigden G, Nyang’wa BT, du Cros P, Varaine F, Hughes J, Rich M, et al. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ. 2014 Jan 1;92(1):68–74.
16. A phase 3 study assessing the safety and efficacy of bedaquiline plus PA-824 plus linezolid in subjects with drug resistant pulmonary tuberculosis [Internet]. Bethesda: National Institutes of Health; 2015. Available from: https://clinicaltrials.gov/ct2/show/NCT02333799 [cited 2015 Apr 13].
17. Clayden P, Collins S, Daniels C, Frick M, Harrington M, Horn T, et al. 2014 pipeline report. London: HIV i-Base/Treatment Action Group; 2014. Available from: http://www.treatmentactiongroup.org/sites/g/fles/ g450272/f/201407/2014%20Pipeline%20Report%20Full.pdf [cited 2015 Apr 13].
18. DR-TB clinical trial progress report. Cambridge: RESIST-TB; 2015. Available from: http://www.resisttb.org/?page_id=1602 [cited 2015 Feb 25].
19. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, et al., Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002 Aug 17;360(9332):528–34. http://dx.doi.org/10.1016/S0140-6736(02)09742-8
20. Jindani A, Harrison TS, Nunn AJ, Phillips P P, Churchyard GJ, Charalambous S, et al.; RIFAQUIN Trial Team. High-dose rifapentine with moxifoxacin for pulmonary tuberculosis. N Engl J Med. 2014 Oct 23;371(17):1599–608. http://dx.doi.org/10.1056/NEJMoa1314210
21. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, et al.; OFLOTUB/Gatifoxacin for Tuberculosis Project. A four-month gatifoxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014 Oct 23;371(17):1588–98. http://dx.doi.org/10.1056/NEJMoa1315817
22. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Geneva: World Health Organization; 2013
23. The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance. Geneva: World Health Organization; 2014.
24. Policy implementation package for new TB drug introduction. Geneva: World Health Organization; 2014.
25. Boehme CC, Nicol M P, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011 Apr 30;377(9776):1495–505. http://dx.doi.org/10.1016/S0140-6736(11)60438-8
26. Srivastava S, Pasipanodya JG, Meek C, Lef R, Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis. 2011 Dec 15;204(12):1951–9. http://dx.doi.org/10.1093/infdis/jir658
27. Louw GE, Warren RM, Gey van Pittius NC, McEvoy CR, Van Helden PD, Victor TC. A balancing act: efux/infux in mycobacterial drug resistance. Antimicrob Agents Chemother. 2009 Aug;53(8):3181–9. http://dx.doi.org/10.1128/AAC.01577-08
28. Gumbo T. Biological variability and the emergence of multidrug-resistant tuberculosis. Nat Genet. 2013 Jul;45(7):720–1. http://dx.doi. org/10.1038/ng.2675
29. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifoxacin combinations: a randomised trial. Lancet. 2012 Sep 15;380(9846):986–93. http://dx.doi.org/10.1016/S0140-6736(12)61080-0
30. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010 Sep 1;182(5):684–92. http://dx.doi.org/10.1164/rccm.201001-0077OC
31. Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, et al. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014 Oct;18(10):1180–7. http://dx.doi.org/10.5588/ijtld.14.0100
32. Piubello A, Harouna SH, Souleymane MB, Boukary I, Morou S, Daouda M, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis. 2014 Oct;18(10):1188–94. http://dx.doi.org/10.5588/ijtld.13.0075
33. The use of short regimens for treatment of multidrug-resistant tuberculosis [Internet]. Geneva: World Health Organization; 2013. Available from: http://www.who.int/tb/challenges/mdr/short_regimen_use/en/# [cited 2013 Dec 19].
34. Khan MS, Coker RJ. How to hinder tuberculosis control: fve easy steps. Lancet. 2014 Aug 23;384(9944):646–8. http://dx.doi.org/10.1016/ S0140-6736(14)61175-2
35. Ben Amor Y, Day MS, Schluger NW. Preventing the next generation of extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2010 May;14(5):525–7.
36. Cegielski J P. Extensively drug-resistant tuberculosis: “there must be some kind of way out of here”. Clin Infect Dis. 2010 May 15;50(s3) Suppl 3:S195–200. http://dx.doi.org/10.1086/651491
37. Mitchison DA. Chemotherapy of tuberculosis: a bacteriologist’s viewpoint. BMJ. 1965 May 22;1(5446):1333–40. http://dx.doi.org/10.1136/bmj.1.5446.1333
38. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis. 1998 Jan;2(1):10–5.
39. Farhat MR, Shapiro BJ, Kieser KJ, Sultana R, Jacobson KR, Victor TC, et al. Genomic analysis identifes targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet. 2013 Oct;45(10):1183–9. http://dx.doi.org/10.1038/ng.2747
40. Almeida Da Silva PE, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother. 2011 Jul;66(7):1417–30. http://dx.doi.org/10.1093/jac/dkr173
41. Colijn C, Cohen T, Ganesh A, Murray M. Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapy. PLoS ONE. 2011;6(3):e18327. http://dx.doi.org/10.1371/journal.pone.0018327
42. Cegielski J P, Dalton T, Yagui M, Wattanaamornkiet W, Volchenkov GV, Via LE, et al.; Global Preserving Effective TB Treatment Study (PETTS) Investigators. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2014 Oct 15;59(8):1049–63. http://dx.doi.org/10.1093/cid/ciu572
43. Isaakidis P, Varghese B, Mansoor H, Cox HS, Ladomirska J, Saranchuk P, et al. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS ONE. 2012;7(7):e40781. http://dx.doi.org/10.1371/journal.pone.0040781
44. Wu S, Zhang Y, Sun F, Chen M, Zhou L, Wang N, et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Am J Ther. 2013 Nov 26. Epub. http://dx.doi.org/10.1097/01.mjt.0000433951.09030.5a
45. Harris T, Bardien S, Schaaf HS, Petersen L, De Jong G, Fagan JJ. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. S Afr Med J. 2012 Jun;102(6 Pt 2):363–6.
46. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS ONE. 2009;4(9):e7186. http://dx.doi.org/10.1371/journal.pone.0007186